Author | Eisuke Fukuma, MD

Articles

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

July 01, 1999

ByMamoru Fukuda, MD|Susumu Yamaguchi, MD|Tomohiko Ohta, MD|Yoshiaki Nakayama, MD|Haruki Ogata, MD|Kaname Shimizu, MD|Toru Nishikawa, MD|Yukihiro Adachi, MD|Eisuke Fukuma, MD

We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), uracil and tegafur (UFT), and tamoxifen (Nolvadex) (CAUT), designed as